Eli Lilly & Co (LLY) Shows Promising Signs of Uptrend Continuation
Eli Lilly & Co (LLY) is expected to maintain its upward trajectory, according to A.I.dvisor's predictions. With a projected growth of 2% to reach $451.18 or higher within the next week, the stock shows promising signs of an Uptrend continuation. This positive outlook is supported by a winning streak that has extended for consecutive weeks, indicating strong momentum.
Join our team and immerse yourself in the world of AI-driven trading with Eli Lilly & Co. Experience the power of our Bearish S&P 500 Swing Trader: one position only (TA), meticulously crafted using advanced technical analysis (TA) techniques.
With our AI-powered approach, we focus on identifying optimal swing trading opportunities within the S&P 500 index. Eli Lilly & Co has caught our attention as a bearish candidate, presenting an intriguing position for potential profits. By leveraging our cutting-edge technology, we have devised a strategy tailored to capitalize on this market sentiment.
One notable indicator that suggests further upside potential for LLY is the Aroon Indicator. On June 01, 2023, the AroonUp line crossed above 70, while the AroonDown line remained below 30. This bullish signal indicates that the stock may be setting up for a potential upward move. Traders may consider buying LLY or exploring call options to capitalize on this anticipated trend continuation. Looking at historical data, A.I.dvisor identified 353 similar instances where the Aroon Indicator exhibited a similar pattern, and in 240 of those cases, the stock moved higher in the subsequent days. This translates to an encouraging 68% probability of a move higher for LLY.
Furthermore, there is a notable correlation between LLY and MRK over the past year. These two tickers have shown a loose lockstep movement around 57% of the time. This statistical relationship suggests that if LLY experiences a jump in price, there is a possibility that MRK could also see price increases. Investors interested in LLY may want to keep an eye on MRK as well for potential opportunities.
As investors assess the prospects of Eli Lilly & Co (LLY), it's important to consider both short-term and long-term perspectives. The short-term outlook, driven by technical analysis indicators, indicates an Uptrend continuation with a 78% probability. On the other hand, fundamental analysis ratings provide insights into the long-term valuation of the stock. By considering these different perspectives, investors can make informed decisions regarding their investment strategies.
Eli Lilly & Co (LLY) shows promising signs of an Uptrend continuation, supported by A.I.dvisor's projections and positive technical indicators. With the stock's winning streak, the bullish Aroon Indicator, and a correlation with MRK, investors may find opportunities for growth and potential price increases in the coming weeks.
LLY in upward trend: price may jump up because it broke its lower Bollinger Band on March 05, 2026
LLY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 32 cases where LLY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in of 386 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on March 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for LLY turned negative on March 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
LLY moved below its 50-day moving average on March 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LLY crossed bearishly below the 50-day moving average on January 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for LLY entered a downward trend on February 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.113) is normal, around the industry mean (9.338). LLY has a moderately high P/E Ratio (42.844) as compared to the industry average of (22.856). Projected Growth (PEG Ratio) (1.056) is also within normal values, averaging (2.282). LLY has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.025). LLY's P/S Ratio (13.569) is very high in comparison to the industry average of (3.971).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement